Trabectedin for Recurrent Grade II or III Meningioma: a Randomized Phase II Study of the EORTC Brain Tumor Group
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Sep 2017
At a glance
- Drugs Trabectedin (Primary)
- Indications Meningioma
- Focus Therapeutic Use
- 31 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 04 Feb 2016 New source identified and integrated (United Kingdom Clinical Research Network; 20311)
- 21 Sep 2015 According to EORTC and PharmaMar media release, company has enrolled first patient for this trial.